Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Release Date: March 14, 2025

Expiration Date: March 14, 2026

Activity Overview

Thousands of cases of advanced or metastatic non–small cell lung cancer (NSCLC) harbor rearrangements or mutations in the ALK gene, creating an opportunity for targeted therapy. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment, highlighting the need for comprehensive and timely biomarker testing in newly-diagnosed patients.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the 22^nd Annual Winter Lung Cancer Conference® held in January/February 2025. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with ALK-positive advanced or metastatic NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Target Audience

This educational activity is primarily directed at oncologists, oncology nurses, advanced practice providers, pharmacists, and other health care professionals involved in the care and treatment of people with ALK+ mNSCLC.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Integrate molecular testing into treatment planning for patients with mNSCLC
• Compare the efficacy and safety of ALK inhibitors in the first-line treatment of patients with ALK-positive mNSCLC
• Select first-line treatment for patients with ALK-positive mNSCLC incorporating clinical trial evidence, guidelines, and patient-related factors
• Incorporate recommended strategies for monitoring and managing adverse events associated with ALK inhibitors in patients with mNSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.